Pembrolizumab, an anti-PD-1 antibody, has been increasingly used in the literature surrounding malignancies such as melanoma and other non-Hodgkin lymphomas and has been explored in recurrent/relapsed (R/R) mature PTCL with an ORR of 33% (118). Here, PDCD1 is linked to melanoma.